Lenalidomide Monotherapy in R/R DLBCL
RE-MIND
An Observational Retrospective Cohort Study of Lenalidomide Monotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) to Generate a Historical Control for Clinical Trial MOR208C203 (RE-MIND)
1 other identifier
observational
490
4 countries
57
Brief Summary
This observational study is designed to characterise the effectiveness of lenalidomide monotherapy in the treatment of R/R DLBCL and to compare the results with the efficacy outcomes of a tafasitamab-lenalidomide combination therapy in the clinical trial MOR208C203 (L-MIND)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2019
57 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 12, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 25, 2019
CompletedFirst Submitted
Initial submission to the registry
October 31, 2019
CompletedFirst Posted
Study publicly available on registry
November 4, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
August 25, 2020
CompletedAugust 24, 2022
August 1, 2022
5 months
October 31, 2019
August 23, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Best overall/objective response rate (ORR)
Proportion of patients with complete response (CR) or partial response (PR) as best response achieved at any time during the study
Through study completion, an average of 9 months
Secondary Outcomes (3)
Overall survival
Through study completion, an average of 9 months
Complete response rate
Through study completion, an average of 9 months
Disease control rate
Through study completion, an average of 9 months
Eligibility Criteria
R/R DLBCL patients not eligible for HDC followed by ASCT who were treated with lenalidomide monotherapy
You may qualify if:
- Histologically confirmed diagnosis of DLBCL
- Relapsed/refractory to at least one previous systemic therapy for DLBCL
- Received at least one, but no more than three previous systemic regimens for the treatment of DLBCL, including at least one anti-CD20 containing therapy
- Received lenalidomide monotherapy for R/R DLBCL while being considered not eligible for an ASCT
You may not qualify if:
- CNS involvement by lymphoma
- Patients who received lenalidomide in combination with another anti-lymphoma therapy (including radiation)
- Previously treated with anti-CD19-targeted therapy or immunomodulatory drugs
- Patients who previously underwent allogeneic SCT
- Known simultaneous detection of MYC and BCL2 or BCL6 translocation according to FISH
- Patients with a history of other malignancies within 5 years prior to lenalidomide treatment start
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- MorphoSys AGlead
Study Sites (57)
MorphoSys Research Site
Rochester, Minnesota, 55905, United States
MorphoSys Research Site
St Louis, Missouri, 63110, United States
MorphoSys Research Site
Manhasset, New York, 11030, United States
MorphoSys Research Site
New York, New York, 10013, United States
MorphoSys Research Site
Rochester, New York, 14642, United States
MorphoSys Research Site
Dublin, Ohio, 43017, United States
MorphoSys Research Site
Charleston, South Carolina, 29425, United States
MorphoSys Research Site
Greenville, South Carolina, 29615, United States
MorphoSys Research Site
Bordeaux, 76038, France
MorphoSys Research Site
Le Mans, 72037, France
MorphoSys Research Site
Lille, 59037, France
MorphoSys Research Site
Lyon, 69495, France
MorphoSys Research Site
Paris, 75010, France
MorphoSys Research Site
Paris, 75743, France
MorphoSys Research Site
Poitiers, 86000, France
MorphoSys Research Site
Pontoise, 95300, France
MorphoSys Research Site
Rouen, 76038, France
MorphoSys Research Site
Toulouse, 31059, France
MorphoSys Research Site
Tours, 37044, France
MorphoSys Research Site
Aviano, 33081, Italy
MorphoSys Research Site
Bergamo, 24127, Italy
MorphoSys Research Site
Bologna, 40138, Italy
MorphoSys Research Site
Brescia, 25123, Italy
MorphoSys Research Site
Como, 22100, Italy
MorphoSys Research Site
Cuneo, 12100, Italy
MorphoSys Research Site
Florence, 50134, Italy
MorphoSys Research Site
Meldola, 47014, Italy
MorphoSys Research Site
Milan, 20132, Italy
MorphoSys Research Site
Milan, 20141, Italy
MorphoSys Research Site
Milan, 20162, Italy
MorphoSys Research Site
Modena, 41124, Italy
MorphoSys Research Site
Napoli, 80131_2, Italy
MorphoSys Research Site
Napoli, 80131, Italy
MorphoSys Research State
Novara, 28100, Italy
MorphoSys Research Site
Padua, 35128, Italy
MorphoSys Research Site
Parma, 43126, Italy
MorphoSys Research Site
Pavia, 27100, Italy
MorphoSys Research Site
Perugia, 06129, Italy
MorphoSys Research Site
Piacenza, 29121, Italy
MorphoSys Research Site
Ponderano, 13875, Italy
MorphoSys Research Site
Ravenna, 48121, Italy
MorphoSys Research Site
Reggio Emilia, 42132, Italy
MorphoSys Research Site
Rimini, 47923, Italy
MorphoSys Research Site
Roma, 00128, Italy
MorphoSys Research Site
Roma, 00161, Italy
MorphoSys Research Site
Roma, 00189, Italy
MorphoSys Research Site
Salerno, 84131, Italy
MorphoSys Research Site
San Giovanni Rotondo, 71013, Italy
MorphoSys Research Site
Torino, 10126_2, Italy
MorphoSys Research Site
Torino, 10126, Italy
MorphoSys Research Site
Torino, 10128, Italy
MorphoSys Research Site
Udine, 33100, Italy
MorphoSys Research Site
Verona, 37100, Italy
MorphoSys Research Site
Vicenza, 36100, Italy
MorphoSys Research Site
Barcelona, 08003, Spain
MorphoSys Research Site
Madrid, 28041, Spain
MorphoSys Research Site
Salamanca, 37007, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 31, 2019
First Posted
November 4, 2019
Study Start
April 12, 2019
Primary Completion
August 25, 2019
Study Completion
August 25, 2020
Last Updated
August 24, 2022
Record last verified: 2022-08